AEON Biopharma (AEON) via Priveterra Acq (PMGM) deck

AEON is a clinical stage biopharmaceutical company focused on developing ABP-450 (prabotulinumtoxinA) injection for the treatment of debilitating medical conditions with an initial focus on the neurology and gastroenterology markets.

Debarshi Ghosh

This post is for subscribers only


Already have an account? Log in